Business
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone - Data indicates combination of evorpacept plus R2 was well-tolerated and provides impressive anti-tumor activity in frontline treatment setting - While longer follow up matures, minimal residual disease (MRD) eradication rate with this novel regimen will
About this update from Alx Oncology Holdings Inc.
[{"type":"image","alt":"ALX Oncology","displaySize":"","headline":null,"caption":"ALX Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":195,"url":"https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tBYkx9_bHbgV6zgiof22Rw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/470f956a3deddaf81b04c64bb1806e3d","width":300,"height":195}},"lazy":false},{"type":"text","content":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone ","length":243,"tagName":"p"},{"type":"text","content":"- Data indicates combination of evorpacept plus R2 was well-tolerated and provides impressive anti-tumor activity in frontline treatment setting ","length":144,"tagName":"p"},{"type":"text","content":"- While longer follow up matures, minimal residual disease (MRD) eradication rate with this novel regimen will be evaluated ","length":123,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that positive data from a Phase 2 investigator-sponsored trial (IST) of evorpacept, in combination with standard-of-care rituximab and lenalidomide, for patients with indolent B-cell non-Hodgkin lymphoma (iNHL) is being presented Sunday, December 7 during a poster presentation at the American Society of Hematology (ASH) Annual Meeting 2025 in Orlando, Florida.","length":651,"tagName":"p"},{"type":"text","content":"“We are excited to see the results of this Phase 2 study in frontline indolent non-Hodgkin lymphoma patients, where the addition of evorpacept added a meaningful benefit over the historical data for the standard-of-care regimen of rituximab and lenalidomide,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “Dr. Strati pursued this frontline study after seeing promising activity using the same combination in the relapsed refractory setting, which wa...